Johan Langenhuijsen1, Alison Birtle2, Tobias Klatte3, Francesco Porpiglia4, Marc-Oliver Timsit5. 1. Department of Urology, Radboud University Medical Centre, Nijmegen, The Netherlands. Electronic address: Hans.Langenhuijsen@radboudumc.nl. 2. Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK. 3. Department of Urology, Medical University of Vienna, Vienna, Austria. 4. Division of Urology, San Luigi Gonzaga Hospital, School of Medicine, Torino, Italy. 5. Department of Urology and Transplant Surgery, HEGP-Necker, APHP Université Paris Descartes, Paris, France.
Abstract
CONTEXT: Controversy exists regarding the choice for surgical approach and the role of lymph node dissection (LND) in adrenocortical carcinoma (ACC) treatment. ACC surgery is increasingly advocated to be performed in specialist referral centres. OBJECTIVE: To review systematically the evidence of oncologic outcomes for ACC surgery by open adrenalectomy (OA) or laparoscopic adrenalectomy (LA), and for concomitant LND. The influence of surgical volume is also analysed. EVIDENCE ACQUISITION: A systematic review of Ovid Medline, Embase, and the Cochrane Library was performed in June 2015 according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Twenty-six publications were selected for inclusion in the analysis. Meta-analyses were performed when appropriate. EVIDENCE SYNTHESIS: Included studies reported on oncologic outcomes after surgical treatment of ACC (11 studies), compared different surgical approaches (7 studies), evaluated the role of LND (3 studies), and analysed the effect of surgical volume on outcome (5 studies). From the available studies and the meta-analysis, no differences were found in the rate of positive surgical margins, disease-free survival, and overall survival between OA and LA in localised disease. In patients with histologically proven positive lymph nodes, a shorter time to recurrence was seen when no proper LND was performed. A trend for better recurrence-free survival and disease-specific survival after LND was found. In high-volume centres, more aggressive and open surgery was performed. In low-volume centres, higher local recurrence and distant metastases rates, and a shorter time to recurrence were seen. Our findings are limited due to the low level of evidence of selected studies, patient and disease heterogeneity, and heterogeneous surgeon populations. CONCLUSIONS: After adequate clinical staging for localised disease, LA is as effective and oncologically safe as OA, as long as oncologic principles are respected. LA should be performed by surgeons with extensive experience in laparoscopic adrenal surgery in high-volume centres. Patients with locally advanced disease and metastatic disease, for debulking purposes, should be operated on extensively with open surgery with adequate margins and concomitant LND to optimise staging, which may contribute to survival in locally advanced disease. PATIENT SUMMARY: Laparoscopic surgery for localised adrenocortical carcinoma is safe and effective when performed by expert surgeons in high-volume centres. Patients with more extensive tumours should be operated with open surgery; lymph node dissection is mainly applied to determine the stage of the disease.
CONTEXT: Controversy exists regarding the choice for surgical approach and the role of lymph node dissection (LND) in adrenocortical carcinoma (ACC) treatment. ACC surgery is increasingly advocated to be performed in specialist referral centres. OBJECTIVE: To review systematically the evidence of oncologic outcomes for ACC surgery by open adrenalectomy (OA) or laparoscopic adrenalectomy (LA), and for concomitant LND. The influence of surgical volume is also analysed. EVIDENCE ACQUISITION: A systematic review of Ovid Medline, Embase, and the Cochrane Library was performed in June 2015 according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Twenty-six publications were selected for inclusion in the analysis. Meta-analyses were performed when appropriate. EVIDENCE SYNTHESIS: Included studies reported on oncologic outcomes after surgical treatment of ACC (11 studies), compared different surgical approaches (7 studies), evaluated the role of LND (3 studies), and analysed the effect of surgical volume on outcome (5 studies). From the available studies and the meta-analysis, no differences were found in the rate of positive surgical margins, disease-free survival, and overall survival between OA and LA in localised disease. In patients with histologically proven positive lymph nodes, a shorter time to recurrence was seen when no proper LND was performed. A trend for better recurrence-free survival and disease-specific survival after LND was found. In high-volume centres, more aggressive and open surgery was performed. In low-volume centres, higher local recurrence and distant metastases rates, and a shorter time to recurrence were seen. Our findings are limited due to the low level of evidence of selected studies, patient and disease heterogeneity, and heterogeneous surgeon populations. CONCLUSIONS: After adequate clinical staging for localised disease, LA is as effective and oncologically safe as OA, as long as oncologic principles are respected. LA should be performed by surgeons with extensive experience in laparoscopic adrenal surgery in high-volume centres. Patients with locally advanced disease and metastatic disease, for debulking purposes, should be operated on extensively with open surgery with adequate margins and concomitant LND to optimise staging, which may contribute to survival in locally advanced disease. PATIENT SUMMARY: Laparoscopic surgery for localised adrenocortical carcinoma is safe and effective when performed by expert surgeons in high-volume centres. Patients with more extensive tumours should be operated with open surgery; lymph node dissection is mainly applied to determine the stage of the disease.
Authors: Kevin B Ginsburg; Alberto A Castro Bigalli; Jared P Schober; David Perlman; Elizabeth A Handorf; David Y T Chen; Richard E Greenberg; Rosalia Viterbo; Robert G Uzzo; Alexander Kutikov; Marc C Smaldone; Andres F Correa Journal: Urol Oncol Date: 2022-06-17 Impact factor: 2.954
Authors: Marilyne Daher; Jeena Varghese; Stephen K Gruschkus; Camilo Jimenez; Steven G Waguespack; Sara Bedrose; Lina Altameemi; Hadil Bazerbashi; Aung Naing; Vivek Subaiah; Matthew T Campbell; Amishi Y Shah; Miao Zhang; Rahul A Sheth; Jose A Karam; Christopher G Wood; Nancy D Perrier; Paul H Graham; Jeffery E Lee; Mouhammed Amir Habra Journal: J Clin Endocrinol Metab Date: 2022-04-19 Impact factor: 6.134
Authors: Olivia M Delozier; Zachary E Stiles; Benjamin W Deschner; Justin A Drake; Jeremiah L Deneve; Evan S Glazer; Miriam W Tsao; Danny Yakoub; Paxton V Dickson Journal: Ann Surg Oncol Date: 2020-07-11 Impact factor: 5.344